메뉴 건너뛰기




Volumn 2, Issue 3, 2009, Pages 195-196

Prostaglandin inhibition and cardiovascular risk: Maybe timing really is everything

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; EFLORNITHINE; ETORICOXIB; IBUPROFEN; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PROSTAGLANDIN; PROSTANOID RECEPTOR; PROTON PUMP INHIBITOR; ROFECOXIB; SALSALATE; SULINDAC; TRAMADOL;

EID: 68349091390     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0245     Document Type: Review
Times cited : (4)

References (17)
  • 2
    • 0043031147 scopus 로고    scopus 로고
    • Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract
    • James MW, Hawkey CJ. Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract. Br J Clin Pharmacol 2003;56:146-155
    • (2003) Br J Clin Pharmacol , vol.56 , pp. 146-155
    • James, M.W.1    Hawkey, C.J.2
  • 4
    • 34249310645 scopus 로고    scopus 로고
    • Cardiovascular risk, hypertension, and NSAIDs
    • White WB. Cardiovascular risk, hypertension, and NSAIDs. Curr Rheumatol Rep 2007;9:36-43.
    • (2007) Curr Rheumatol Rep , vol.9 , pp. 36-43
    • White, W.B.1
  • 6
    • 34247464709 scopus 로고    scopus 로고
    • Use of nonsteroidal antiinflammatory drugs: An update for clinicians: a scientific statement from the American Heart Association
    • DOI 10.1161/CIRCULATIONAHA.106.181424
    • Antmann EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal anti-inflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007;115:1634-1642 (Pubitemid 46648649)
    • (2007) Circulation , vol.115 , Issue.12 , pp. 1634-1642
    • Antman, E.M.1    Bennett, J.S.2    Daugherty, A.3    Furberg, C.4    Roberts, H.5    Taubert, K.A.6
  • 7
    • 13444263619 scopus 로고    scopus 로고
    • Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study
    • Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005;365:475-481
    • (2005) Lancet , vol.365 , pp. 475-481
    • Graham, D.J.1    Campen, D.2    Hui, R.3
  • 8
    • 33847373072 scopus 로고    scopus 로고
    • Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)
    • ADAPT Research Group
    • Martin BK, Breitner JCS, Evans D; ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials 2006;1:e33.
    • (2006) PLoS Clin Trials , vol.1
    • Martin, B.K.1    Breitner, J.C.S.2    Evans, D.3
  • 9
    • 55549132996 scopus 로고    scopus 로고
    • Difluoromethylomithine plus sulindac for the prevention of sporadic colorectal adenomas: A randomized placebo-controlled, double-blind trial
    • Meyskens FL, McLaren CE, Pelot D, et al. Difluoromethylomithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res 2008;1:32-38
    • (2008) Cancer Prev Res , vol.1 , pp. 32-38
    • Meyskens, F.L.1    McLaren, C.E.2    Pelot, D.3
  • 10
    • 0034702914 scopus 로고    scopus 로고
    • Cyclooxygenase-1 and 2-dependent prostacyclin formation in patients with atherosclerosis
    • Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and 2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000;102:840-845
    • (2000) Circulation , vol.102 , pp. 840-845
    • Belton, O.1    Byrne, D.2    Kearney, D.3    Leahy, A.4    Fitzgerald, D.J.5
  • 13
    • 12844278633 scopus 로고    scopus 로고
    • Cyclooxygenases, thromboxane, and atherosclerosis: Plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism
    • DOI 10.1161/01.CIR.0000153386.95356.78
    • Egan KM, Wang M, Fries S, et al. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 2005;111:334-342 (Pubitemid 40165341)
    • (2005) Circulation , vol.111 , Issue.3 , pp. 334-342
    • Egan, K.M.1    Wang, M.2    Lucitt, M.B.3    Zukas, A.M.4    Pure, E.5    Lawson, J.A.6    Fitzgerald, G.A.7
  • 14
    • 20544451804 scopus 로고    scopus 로고
    • Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins
    • Rabausch K, Bretschneider E, Sarbia M, et al. Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins. Circ Res 2005;96:e1-4.
    • (2005) Circ Res , vol.96
    • Rabausch, K.1    Bretschneider, E.2    Sarbia, M.3
  • 15
    • 67549105888 scopus 로고    scopus 로고
    • Five year efficacy and safety analysis of the Adenoma Prevention with Celecoxib (APC) trial
    • Bertagnolli MM, Eagle CJ, Zauber AG, et al. Five year efficacy and safety analysis of the Adenoma Prevention with Celecoxib (APC) trial. Cancer Prev Res 2009.
    • (2009) Cancer Prev Res
    • Bertagnolli, M.M.1    Eagle, C.J.2    Zauber, A.G.3
  • 16
    • 33748517838 scopus 로고    scopus 로고
    • Effect of celecoxib on cardiovascular events and blood pressure in two trials for prevention of colorectal adenomas
    • Solomon SD, Pfeffer MA, McMurray JJ, et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for prevention of colorectal adenomas. Circulation 2006;1028-1035
    • (2006) Circulation , pp. 1028-1035
    • Solomon, S.D.1    Pfeffer, M.A.2    McMurray, J.J.3
  • 17
    • 68349123550 scopus 로고    scopus 로고
    • Baseline cardiovascular risk in cancer chemoprevention clinical trials involving NSAIDs: Analysis of cardiovascular toxicity from a randomized placebo-controlled, double-blind trial of difluoromethylomithine plus sulindac for the prevention of sporadic colorectal adenomas
    • Zell JA, Pelot D, Chen W-P, McLaren CE, Gemer EW, Meyskens FL. Baseline cardiovascular risk in cancer chemoprevention clinical trials involving NSAIDs: analysis of cardiovascular toxicity from a randomized placebo-controlled, double-blind trial of difluoromethylomithine plus sulindac for the prevention of sporadic colorectal adenomas. Cancer Prev Res 2009;2:209-212
    • (2009) Cancer Prev Res , vol.2 , pp. 209-212
    • Zell, J.A.1    Pelot, D.2    Chen, W.-P.3    McLaren, C.E.4    Gemer, E.W.5    Meyskens, F.L.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.